HC Wainwright Has Negative Estimate for LXEO FY2024 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Analysts at HC Wainwright reduced their FY2024 EPS estimates for Lexeo Therapeutics in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($3.22) per share for the year, down from their prior forecast of ($2.75). HC Wainwright currently has a "Buy" rating and a $23.00 target price on the stock. The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Lexeo Therapeutics' Q4 2024 earnings at ($0.90) EPS, Q1 2025 earnings at ($0.93) EPS, Q2 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($1.00) EPS and FY2025 earnings at ($3.84) EPS.

Several other research firms have also commented on LXEO. Leerink Partners reduced their price target on Lexeo Therapeutics from $20.00 to $19.00 and set an "outperform" rating on the stock in a report on Wednesday, November 13th. Chardan Capital increased their price objective on Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, August 13th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Lexeo Therapeutics has an average rating of "Buy" and a consensus target price of $22.71.

Lexeo Therapeutics Trading Down 9.8 %

Lexeo Therapeutics stock traded down $0.65 during trading on Monday, reaching $6.00. 503,828 shares of the company were exchanged, compared to its average volume of 251,480. The stock's 50 day simple moving average is $9.01 and its two-hundred day simple moving average is $12.23. The company has a market capitalization of $198.40 million and a P/E ratio of -1.93. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 9.38. Lexeo Therapeutics has a 52-week low of $5.81 and a 52-week high of $22.33.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets acquired a new stake in Lexeo Therapeutics during the 1st quarter worth approximately $75,000. American International Group Inc. acquired a new stake in shares of Lexeo Therapeutics in the first quarter valued at $79,000. Values First Advisors Inc. purchased a new position in Lexeo Therapeutics in the third quarter valued at $67,000. Rhumbline Advisers boosted its holdings in Lexeo Therapeutics by 37.3% in the second quarter. Rhumbline Advisers now owns 13,357 shares of the company's stock valued at $214,000 after purchasing an additional 3,627 shares during the period. Finally, MetLife Investment Management LLC grew its stake in Lexeo Therapeutics by 121.5% during the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company's stock worth $129,000 after purchasing an additional 7,803 shares in the last quarter. Hedge funds and other institutional investors own 60.67% of the company's stock.

Insiders Place Their Bets

In related news, CEO Richard Nolan Townsend sold 5,000 shares of the business's stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $8.10, for a total value of $40,500.00. Following the sale, the chief executive officer now owns 120,695 shares in the company, valued at approximately $977,629.50. The trade was a 3.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 12,500 shares of company stock worth $113,300 over the last ninety days. Corporate insiders own 4.50% of the company's stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.